



(51) International Patent Classification:

B64C 39/06 (2006.01)

(21) International Application Number:

PCT/IB2020/055128

(22) International Filing Date:

29 May 2020 (29.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/855,040 31 May 2019 (31.05.2019) US

62/944,698 06 December 2019 (06.12.2019) US

(71) Applicants: **MEDIMMUNE, LLC** [US/US]; One MedImmune Way, Gaithersburg, Maryland 20878 (US). **DANA-FARBER CANCER INSTITUTE, INC** [US/US]; 450 Brookline Avenue, BP376, Boston, Massachusetts 02215 (US).

(72) Inventors: **KINNEER, Krista**; MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **TICE, David Alan**; MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **COATS, Steven**; MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **TAI, Yu-Tzu**; DANA-FARBER CANCER INSTITUTE, INC, 450 Brookline Avenue/10BP-372A, Boston, Massachusetts 02215 (US). **ANDERSON, Kenneth**; DANA-FARBER CANCER INSTITUTE, INC, 450 Brookline Avenue/10BP-372A, Boston, Massachusetts 02215 (US).

(74) Agent: **DISE, Rebecca S.**; AstraZeneca / MedImmune, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: COMBINATION THERAPY

(57) Abstract: The disclosure relates to methods and compositions for the treatment of a B-cell malignancy. Specifically, the disclosure relates to a B-cell malignancy medicament or composition, comprising: (a) an antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof that binds to B-cell maturation antigen (BCMA), conjugated to a nucleic acid cross-linking agent; and (b) a proteasome inhibitor.

